SCHEMBL6440485

SCHEMBL6440485

COc1ccc2c(c1)COc1c-2ccc2cc(OC)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
ALOX12 P18054 1/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
ALOX5 P09917 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2A6 P11509 1/20 0.40
PRF1 P14222 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706914 0.91 SIRT2 (0.38) HSP90AA1MAPTKDM4ESMN1; SMN2HPGD
SCHEMBL6437588 0.89 KDM4E (0.46) MAPTKDM4ESMN1; SMN2HPGDNPC1
SCHEMBL6442254 0.85 HTT (0.40) HSP90AA1MAPTKDM4ESMN1; SMN2HPGD
SCHEMBL6440760 0.82 ALDH1A1 (0.49) MAPTKDM4ESMN1; SMN2NPC1ALDH1A1
SCHEMBL3195505 0.81 CYP17A1 (0.44) HSP90AA1MAPTKDM4ESMN1; SMN2HPGD
SCHEMBL6436077 0.81 RXRA (0.46) MAPTKDM4ESMN1; SMN2HPGDNPC1
SCHEMBL6439121 0.79 MAPT (0.39) MAPTKDM4ESMN1; SMN2HPGDNPC1
SCHEMBL205458 0.79 HSD11B1 (0.38) CA1CA2
SCHEMBL6440958 0.78 SMN1; SMN2 (0.38) HSP90AA1MAPTKDM4ESMN1; SMN2HPGD
SCHEMBL3195849 0.78 MAPT (0.49) MAPTKDM4ESMN1; SMN2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453820-B1 SUBSTITUTED 6H-DIBENZO[C,H]CHROMENES AS ESTROGENIC AGENTS WYETH CORP (US) 2005-06-01 EP disclosed
US-6723747-B2 ESTROGEN RECEPTOR MODULATORS USEFUL IN TREATING OR INHIBITING CONDITIONS, DISORDERS, OR DISEASE STATES AT LEAST PARTIALLY MEDIATED BY ESTROGEN DEFICIENCY OR EXCESS, OR WHICH MAY BE TREATED OR INHIBITED THROUGH USE OF ESTROGENIC AGENT WYETH 2004-04-20 US disclosed
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents WYETH 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents ESR2, ESR1, ESRRA HSP90AA1 3652/4885MAPT 4552/4885KDM4E 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.